Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Míreanna comhchosúla

• Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)
  de réir: María‐Victoria Mateos, et al.
  Foilsithe / Cruthaithe: (2017)
• One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone
  de réir: Meletios Α. Dimopoulos, et al.
  Foilsithe / Cruthaithe: (2018)
• Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
  de réir: María‐Victoria Mateos, et al.
  Foilsithe / Cruthaithe: (2019)
• Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
  de réir: María‐Victoria Mateos, et al.
  Foilsithe / Cruthaithe: (2021)
• Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma
  de réir: Bryant, Samantha, et al.
  Foilsithe / Cruthaithe: (2015)